2HA.F Spero Therapeutics Inc.

Healthcare Biotechnology Frankfurt Exchange
0.8460 EUR
Close of Nov 11, 2026
0.8460 2.59
Market cap
EUR 49.3M
P/E
7.1x
P/B
1.31x
ROE
-75.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 2HA.F undervalued?

Graham number
Price0.8460
Graham value1.32
Discount35.9%

2HA.F trades 35.9% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Spero Therapeutics Inc. fundamental analysis

No fundamental analysis for Spero Therapeutics Inc. yet.

Spero Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Spero Therapeutics Inc.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It …

Full company profile